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RATIONALISM AND EMPIRICISM IN
MODERN MEDICINE
WARREN NEWTON*
I
INTRODUCTION
About ten years ago, after fellowships and clinical experience in a commu-
nity setting, I had my first experience as a ward attending in a university hospi-
tal.1  We were working with cardiac patients, and I was struck by the common
treatment each patient received.  No matter what the symptoms, patients re-
ceived an exercise treadmill, an echocardiogram, and were put on a calcium
channel blocker.2  This was remarkable at the time because there were in excess
of thirty randomized controlled trials showing the benefit of beta-blockers, a
different class of medicines, to treat patients following a heart attack.  Indeed,
by 1990, there was initial evidence that calcium channel blockers not only failed
to improve outcomes, but actually made them worse.
The point is not to criticize the medical culture at that hospital—similar ex-
amples can be found at every medical center—but rather to explore why there
was so much fondness for calcium channel blockers.  One factor was the sub-
stantial drug company support of faculty research on silent myocardial ische-
mia.  Another factor was what might be called medical fashion.  The most likely
explanation, however, was more fundamental.  For my cardiology colleagues, it
was biologically plausible that calcium channel blockers were better than beta-
blockers.  Like beta-blockers, calcium channel blockers reduce heart rate and
myocardial wall stress, but they lack the side effects of beta-blockers.  In other
words, what was important to my colleagues was not the outcome of the critical
trials, but our understanding of the mechanisms of disease.
This is an example of the tension between rationalism and empiricism in
medicine.  Rationalism is the search for and emphasis on basic mechanisms of
disease, which then color all clinical decisions.  Empiricism is defined as the
emphasis on the outcomes of individual patients and groups of patients.  My
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2. Calcium channel blockers describes a particular class of medicines.
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thesis is that there is an ongoing and fundamental tension between these two
different ways of thinking.  While these ways of thinking can be complemen-
tary, the tension persists, exploding around specific clinical and legal controver-
sies.  Understanding the tension between rationalism and empiricism provides
important background in considering the role of expert advice.
Part II of this article explores the roots of rationalism and empiricism in the
Hippocratic tradition.  Using the Flexner report as a text, Part III emphasizes
the triumph of the rationalists in the founding of modern medicine.  Part IV
briefly describes the development of clinical epidemiology and the evidence-
based medicine over the last thirty years.  Part VI attempts to explicate how this
tension illuminates fundamental clinical and policy questions that doctors, the
health care system, and the legal system confront today.  My goal is not to pres-
ent a detailed explication of the epistemology of medical science, but rather an
intellectual history3 sketching out what has animated the thinking of clinicians.
II
HIPPOCRATIC ROOTS
The Hippocratic tradition rests on many authors, not just the historical Hip-
pocrates of Cos, but a plethora of later writers through antiquity, from Greece
to Alexandria to Rome.  This article focuses on two major sects of that tradition
that dominated in Alexandria from the fourth century B.C. through Roman
times.4  The dominant medical influence in the classical age was rationalism.
Tracing its origin from Thessalos and Drakan, the sons of Hippocrates, ration-
alism is the oldest of the sects.  Thessalos and Drakans emphasized the impor-
tance of natural philosophy in medicine, believing that “where observation
failed, reason might surprise.”5  The fundamental theory was the doctrine of
“humours” as first taught by Pythagoras:
The body of man has in itself blood, phlegm, yellow bile, and black bile: . . . [N]ow he
enjoys the most perfect health when those elements are duly proportioned to one an-
other in respect of compounding power and bulk and when they are perfectly mingled.
Pain is felt when one of these elements is in defect or excess or is isolated in the body
without being compounded with all the others.6
Thus, health was seen as the proper mixture of humours and disease was an im-
balance.  Most medical writing dealt with disputes about the nature of the hu-
mours, what the substances were, and how the balance of humours was altered
by flow and constriction.  From the perspective of the development of modern
3. See generally FRANKLIN L. BAUMER, MODERN EUROPEAN THOUGHT: CONTINUITY AND
CHANGE IN IDEAS 1600-1950 (1977).
4. It is difficult to access the thinking of the classical Greek authors.  In addition to the linguistic
and cultural barriers, many of the original texts were lost in the fire at Alexandria, and what we know is
through later commentators.  See, e.g., RALPH H. MAJOR, A HISTORY OF MEDICINE (1954); PLINIO
PRIORESCHI, A HISTORY OF MEDICINE (2d ed. 1996); WESLEY D. SMITH, THE HIPPOCRATIC
TRADITION  (1997).
5. See MAJOR, supra note 4, at 150.
6. Id. at 123.
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ideas about medicine, this interest is important primarily because it motivated
the first focused research in human anatomy in Alexandria in the third and sec-
ond century B.C.
For the purposes of my argument, however, it should be stressed that the fo-
cus was on how disease develops or, in modern parlance, on mechanisms of dis-
ease.  This emphasis became a lens through which all of clinical medicine was
seen.  Medical advances were understood to come from deductions concerning
physiology, and the clinical implications were derived directly from the under-
standing of the humours.  Thus, diagnosis was the recognition of the current
balance of the humours, and a disease resulting from an excess of a particular
humour might be treated with a procedure or a substance that depleted that
humour.  There was a tendency to think of disease as having a single cause: a
specific disbalance of the humours.  Prognosis was relatively less important than
other clinical questions.7
The empiricists were a splinter group that detached itself from the rational-
ists in the later part of the third century B.C.  They rose in protest against the
dried formalization of the rationalist school and in response to the anatomic
discoveries.  These discoveries, while brilliant, had contributed little to healing
the sick.  Furthermore, there was concern about the ethics of the dissection, and
particularly the vivisection, practiced by the anatomists of that era.  The empiri-
cists rejected abstractions and general medical theories in favor of observation.
They based their practice on the recollection of past observations and the
knowledge of how similar symptoms had developed, what their outcomes were,
and the determination of similarity between the case at hand and previous
cases.  As Celsus, a later Roman writer, argued,
if theoretical reasoning would have been sufficient, philosophers would be the best
physicians . . . . Often the cause of disease is known as, for example, in cases of injuries
or wounds, but this does not help in the treatment.  As the cause of disease is uncer-
tain and incomprehensible, we should rely on . . . what experience has taught us.8
Authority was a target, “since neither the philosophers nor the physicians can
agree among themselves, therefore one’s reliance should be placed on no man’s
argument, on no man’s authority.”9
To the empiricists, disease was not an entity but a group of systems, each of
which required treatment.  Experience was their lodestar: As Celsus later
framed it, it is not how we digest, but what is digestible that matters.10  As a con-
sequence, the main interest of empiricists lay in therapeutics more than in
mechanisms of disease.  Pharmacology and surgery were their preferred means
to treat disease, and their writings are dominated by discussions of specific
symptoms, remedies, similarities, and outcomes.  The emphasis on therapy had
an impact on how other kinds of clinical questions were addressed.  The empiri-
7. See PRIORESCHI, supra note 4, at 474-563.
8. Id. at 547.
9. See id.
10. See MAJOR, supra note 4, at 151.
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cists did not value looking for the “prime causes” of diseases.  Diagnosis em-
phasized the recognition of discrete symptoms.  In contrast to the rationalists,
the empiricists believed that outcomes was the most important issue, with prog-
nosis as a secondary focus.
III
FLEXNER AT THE FOUNDING OF MODERN MEDICINE
What we understand as modern medicine has at its roots a triumph of ra-
tionalism: the emphasis on the search for basic mechanisms of disease and the
development of therapeutic tools derived from them.  At the turn of the last
century, what we think of as modern medicine was understood as allopathic
medicine.  It was one of a variety of “sects,” which included homeopathy, oste-
opathy, and herbalism.  Despite the clinical breakthroughs in anesthesia, anti-
sepsis/asepsis, bacteriology, and pathology, allopathic medicine was by no
means the most significant of the sects.  Indeed, the homeopathic tradition was
in the ascendancy, having many medical schools and taking care of the elite.
A key event in the development of medicine in the United States was the
publication of the Flexner report.11  Abraham Flexner was a representative of
the Carnegie Foundation, whose major interest was in promoting the develop-
ment of the modern university.  As part of that effort, Flexner was commis-
sioned to study the structure and function of medical education.  Over four
years, he visited all 152 medical colleges in the United States and summarized
his findings in what has come to be known as the Flexner report.  That report,
with the public and private outrage that accompanied it, transformed American
medicine.  Within thirty years, over half of the medical schools in the United
States closed, and those that remained, while heterogenous, were much closer
to the Flexnerian model: substantial emphasis on basic science, integrated into
the university structure, and having a close affiliation with a teaching hospital.
Flexner understood himself to be writing about the structure of modern
medical schools.12  For our purposes, however, Flexner’s report is valuable be-
cause it provides a window on the thinking about rationalism and empiricism at
the time of the founding of modern medicine.  Flexner was contemptuous of the
practitioners of his day, whom he saw almost as mere empiricists, giving out
medications by rote in response to symptoms.  Describing the education system
he wanted to destroy, Flexner observed:
The student’s part was, parrot like, to absorb.  His medical education consisted largely
in getting by heart a prearranged system of correspondences,—an array of symptoms
so set off against a parallel array of doses that, if he noticed the one, he had only to
write down the other: a coated tongue—a course of calomel; a shivery back—a round
quinine.13
11. See ABRAHAM FLEXNER, MEDICAL EDUCATION IN THE UNITED STATES AND CANADA: A
REPORT TO THE CARNEGIE FOUNDATION FOR THE ADVANCEMENT OF TEACHING (1960).
12. See id.
13. Id. at 21.
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Surveying the achievements of Robert Koch, Robert Lister, and particularly
the new Johns Hopkins Medical School, Flexner’s vision was that the modern
physician should be a scientist, trained in the habits and discipline of the basic
sciences of anatomy, physiology, pathology, and microbiology.14  He compared
the clinician to the researcher explicitly:
The main intellectual tool of the investigator is the working hypothesis, or theory, as it
is more commonly called.  The scientist is confronted by a definite situation; he ob-
serves it for the purpose of taking in all the facts.  These suggest to him a line of ac-
tion.  He constructs a hypothesis, as we say.  Upon this he acts, and the practical out-
come of this procedure refutes, confirms, or modifies his theory.  Between theory and
fact, his mind flies like a shuttle; and theory is helpful and important just to the degree
in which it enables him to understand and relate, and control phenomena.  This is es-
sentially the technique of research: wherein it is irrelevant to bedside practice?  The
physician, too, is confronted by a definite situation.  He must needs seize its details,
and only by powers of observation trained in actual experimentation will enable him
to do so.  The patient’s history, conditions and symptoms form his data.  The progress
of science and the scientific practice of medicine employ, therefore, exactly the same
technique.15
At the heart of the modern medical school is the investigation of the basic
mechanisms of disease.  Flexner argued that having faculty doing research is ab-
solutely critical to the new medical school because the researcher’s constant at-
tention to the fundamental mechanisms of disease provides the right milieu for
physicians in training.  While practicing physicians must, as a matter of practi-
cality, spend their time taking care of patients and cannot focus on research,
their temper and temperament have been formed by teachers who are honed at
the edge of basic science.  Flexner created a temple of medicine, in which the
high priests are scientists who illuminate the basic processes of disease.  While it
is important not to oversimplify Flexner’s views—the way of thinking he em-
braced emphasized the importance of fitting facts to theories—his was a tri-
umph of rationalism over empiricism.
Flexner’s vision has been profoundly amplified by the changes in science as
mechanisms of disease have moved farther from the bedside, and in the financ-
ing of medical schools as external support for research has skyrocketed since
World War II.  The orthodoxy of modern medicine is rationalist; a large major-
ity of physicians within academic medical centers and in practice are subspe-
cialists who are experts in a particular set of diseases and focus on particular or-
gan systems or diseases.  Mechanisms of disease dominate medical school
curriculum, as well as much of clinical training.
IV
CLINICAL EPIDEMIOLOGY AND THE RISE OF EVIDENCE-BASED MEDICINE
The rise of clinical epidemiology in the latter half of the twentieth century
represented the empiricists’ response to the rationalists.  The traditional roots
of epidemiology were the Hippocratic emphasis on the distribution of disease in
14. See id. at 55.
15. Id.
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space and time and the empiricist tradition.  In 1946, John Paul argued for the
application of epidemiology to clinical problems.16  This approach was elabo-
rated by David Sackett at McMaster, Alvan Feinstein at Yale, and others in the
1960s and 1970s in a series of books and articles.17  Arguing that clinical epide-
miology is “the basic science of clinical medicine,”18 Sackett and others took the
general approaches of epidemiology—defining a population and assessing ex-
posures—and addressed them to the fundamental clinical questions of causa-
tion, therapy, diagnosis, and prognosis.  The focus on clinical questions under-
scored the importance of studies with humans and emphasized patient-centered
outcomes.  Moreover, use of epidemiologic methods allowed standardized as-
sessment (“critical appraisal”) of the strength of study designs.  The movement
has had different names in different decades and with different audiences: Criti-
cal Appraisal of the Literature, Outcomes Research, Practice Guidelines, and
Evidence-Based Medicine.19
In the 1990s, the term “Evidence-Based Medicine” (“EBM”) began to be
used to label this general area of work.  Sackett defines EBM as “the conscien-
tious, explicit and judicious use of best current evidence in making decisions
about the care of individual patients.”20  What constitutes evidence is in the
mind of the beholder, but the territory Sackett claimed included studies on hu-
mans that include patient-centered outcomes.21  While EBM has had many dif-
ferent expressions, a common approach has been to summarize the available
literature around specific questions of clinical management.  It is common for
techniques of meta-analysis, the statistical combination of similar trials, to
achieve a more precise estimate of effect.
A good example of EBM is the approach taken by David C. Slawson and
Allen F. Shaughnessey to review the available clinical literature for practicing
clinicians.22  Writing about the challenges faced by practicing physicians as they
try to keep up to date, they distinguish between POEMs and DOEs.23  POEM
stands for “Patient Oriented Evidence that Matters,” meaning methodologically
16. J.R. Paul, Clinical Epidemiology, 17 J. CLINICAL INVESTIGATION 539, 539-41 (1938).
17. See, e.g., ALVAN R. FEINSTEIN, CLINICAL EPIDEMIOLOGY: THE ARCHITECTURE OF
CLINICAL RESEARCH (1985); ROBERT H. FLETCHER ET AL., CLINICAL EPIDEMIOLOGY: THE
ESSENTIALS (1996); DAVID L. SACKETT, CLINICAL EPIDEMIOLOGY: A BASIC SCIENCE FOR
CLINICAL MEDICINE (1985).
18. SACKETT,  supra note 17, at ix-xii.
19. The phrase “critical appraisal of the medical literature” was popularized by Sackett and others
at McMaster.  See Warren Newton, Critical Appraisal of the Medical Literature, in INTRODUCTION TO
CLINICAL SKILLS 335 (Mark B. Mengel & Scott A. Fields eds., 1997).  “Practice Guidelines” are at-
tempts to summarize the best available evidence around specific clinical issues.  See U.S. DEP’T OF
HEALTH & HUMAN SERVICES, PUBLIC HEALTH SERVICE, AGENCY FOR HEALTH CARE POLICY AND
RESEARCH, PUB. NO. 93-0550 (Apr. 1993). Outcome research is a more general term referring to
health services research that focuses on significant patient outcomes.
20. David L. Sackett, Evidence-Based Medicine, 23 SPINE 1085, 1085 (1998).
21. See id.
22. See Allen F. Shaughnessy et al., Becoming an Information Master: A Guidebook to the Medical
Information Jungle, 39 J. FAM. PRAC. 489 (1994); David C. Slawson et al., Becoming a Medical Infor-
mation Master: Feeling Good About Not Knowing Everything, 38 J. FAM. PRACT. 505 (1994).
23. See Shaughnessy et al., supra note 22; Slawson et al., supra note 22.
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strong studies that apply to patients with symptoms similar to the physician’s
patients and change practice.  DOE stands for “Disease Oriented Evidence,” or
evidence that relates to the pathophysiology of disease, or uses biochemical
markers as outcomes.  Practicing physicians should search for POEMs and use
DOEs only when there is nothing better.  The critique of traditional biomedical
medical research is radical:  The vast majority of published medical work falls
into the category of DOEs.24  This approach has been incorporated into a series
of magazines and new products for practicing clinicians, and its significance has
been likened to Dolly the sheep by the editors of the British Medical Journal.25
The reaction provoked by EBM has been sharp, as one would anticipate
from its impiety and antagonism to clinical experts.  The tenor of the discussion
can be seen in this comment by a British clinician:
The rise of Evidence Based Medicine has been one of the more remarkable phenom-
ena of the British health scene during the 1990’s . . . . The “fall” of EBM is rather dif-
ferent; since it involves a quasi-theological “fall from grace”: a loss of clinical, scien-
tific and educational integrity, even to the point of decline into a “state of sin” (if
seeking and clinging to power at any cost is seen as sinful).  The moral decline
would—in the normal course of events—be followed in due course by loss of status,
income and power.  However, the EBM barnacle may prove difficult to dislodge now
[sic] it has a grip on the minds of politicians and managers.26
For the purposes of this argument, the emphasis on EBM represents a ren-
aissance of empiricist thinking cast into modern language.  The key questions of
epidemiology—accounting for bias and chance—represent a modern treatment,
with modern analytic tools, of the empiricists’ central question:  How does one
learn from experience?  How does one separate out the role of bias and
chance?  What is going on in medicine now is a war of cultures between those
for whom the mechanisms of disease constitute the best kind of evidence and
those who think that appropriately analyzed outcomes are critical.
V
MODERN MEDICINE: CAUSATION
The tension between rationalism and empiricism illuminates many current
policy disagreements and private injuries.  Most prominent are questions of
clinical causation.  From the rationalist perspective, the causation of disease be-
gins at the cellular level with small changes that alter development and trigger
disease.  Historically, as we have seen, the perceived cause of disease was rela-
tively simple (a disbalance of humours).  Similarly, our modern understanding
of, for example, the development of cancer may have very simple origins (ex-
ternal radiation, for example) followed by complex intermediary events.
Moreover, in public discourse, it is not uncommon for patients, their physicians,
and public officials to have strong and simple beliefs about specific agents and
24. See, e.g., Slawson et al., supra note 22, at 508-11.
25. See Robert Winston, The Promise of Cloning for Human Medicine, 314 BRIT. MED. J. 913
(1997).
26. B.G. Charlton & A. Miles, The Rise and Fall of EBM,  91 Q.  J. MED. 371, 371-74 (1998).
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their impact.  By contrast, an empiricist view is that causation is multifactorial
and may be different in different settings.27  This difference in understanding of
causality is at the root of many of the disagreements about causation in both
policy and private injury.
The controversy around silicone breast implants provides an example of
how this tension plays out in public discourse.  For many years, there has been
some concern that silicone exposure may cause autoimmune diseases, especially
systemic sclerosis.  Silicone is used in many different ways.  The administration
of drugs and parenteral fluids, as well as dialysis and cardiac bypass, depends on
liquid silicone.  But the highest profile use is in silicone breast implants for
women who require reconstruction after breast cancer surgery or for cosmetic
reasons.  The question of causation has become very controversial, fired by liti-
gation as well as scientific dissent.28
The judge overseeing discovery in all federal cases involving silicone-gel-
filled breast implants appointed a neutral group of experts to review the evi-
dence formally.29  This group, led by Dr. Barbara Hulka at the University of
North Carolina, did a formal meta-analysis of studies of the relationship be-
tween breast implants and autoimmune disease.30  They found no association
between silicone breast implants and a variety of different autoimmune dis-
eases, with summary odds ratio of .69 (95%CI: .62-.78).31  Indeed, because the
analysis resulted in an odds ratio significantly less than one, the results suggest
that silicone breast implants may protect against autoimmune diseases.  Fur-
thermore, using standard techniques for evaluating the impact of the exposure
on the population, they concluded that breast implants have minimal effect on
women developing connective tissue disorders.32  Providing an overview of the
controversy, Marcia Angell, the editor of the New England Journal of Medicine,
asked the rhetorical question, “when will science prevail?”33  The science she de-
fended was that of the empiricists.
27. See KENNETH ROTHMAN, MODERN EPIDEMIOLOGY 10-16 (1st ed. 1986).
28. Illustrative breast implant cases include Allison v. McGhan Medical Corp., 184 F. 3d 1300 (11th
Cir. 1999), Hall v. Baxter Healthcare Corp., 947 F. Supp. 1387 (D. Ore. 1996), In re Breast Implant
Cases, 942 F. Supp. 958 (E. & S.D.N.Y. 1996).
29. See In re Silicon Breast Implants Prods. Liab. Litig., 793 F. Supp. 1098 (J.P.M.L. 1992).
30. See Esther C. Janowsky et al., Meta-Analyses of the Relation Between Silicone Breast Implants
and the Risk of Connective-Tissue Diseases, 342 NEW ENG. J. MED. 781 (2000).
31. Odds ratio compares the odds of a person in one group getting a disease or experiencing a par-
ticular outcome with the same odds for a person in another group.  “For instance, if 10% of all people
exposed to chemical develop a disease, compared with 5% of people who are not exposed, the odds of
the disease in the exposed groups are 10/90 = 1/91 compared with 5/95 = 1/19 in the overexposed group.
The odds ratio is 19/9 = 2.1.”  David H. Kaye & David A. Freedman, Reference Guide on Statistics, in
REFERENCE MANUAL ON SCIENTIFIC EVIDENCE 83, 167 (Federal Judicial Ctr. ed., 2d ed. 2000).  A
summary odds ratio aggregates several individual studies.
32. See Janowsky et al., supra note 30, at 781.
33. Marcia Angell, Breast Implants: Protection or Paternalism?, 326 NEW ENG. J. MED. 1695
(1992).
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Scientific reaction has been sharp. The first letter published in response to
the study, written by Eugene Goldberg, took up the issue of what kind of sci-
ence was being used:
As an educator and academic biomedical scientist, I found the lengthy special arti-
cle . . . to be inconsistent with the scientific standards we have come to expect from the
journals . . . . [I]ts credibility is lost because of total disregard of a substantial body of
scientifically sound data on the extraordinary rate of implant failure (now estimated to
involve rupture and gross leakage of silicone in 50 percent of cases after approxi-
mately eight years), the substantial degradation of the silicone shell and gel with time,
the pain and disfigurement that result from contraction of the fibrous capsule, the
chronic inflammation due to immune-system responses involving phagocytosis of fine
silicone droplets by macrophages and giant cells and the spread of silicone throughout
the body.34
At issue is what kind of science is used to address causation.  What Angell de-
fines as science is modern epidemiology, a careful examination of a variety of
studies of the association between exposure and disease in different settings.
Some of the published commentary quarrels with the epidemiological methods
used by Hulka and her colleagues; such commentary shares a focus on patient
outcomes with Hulka and is a very familiar part of the empiricist tradition.  By
contrast, what Goldberg construes as science are the modern biomedical sci-
ences.  Each argument he gives is a possible mechanism of disease.
VI
MODERN MEDICINE: THERAPY
One of the major contributions of clinical epidemiology has been the under-
standing that causation is only one of the fundamental clinical questions.  Of the
other clinical questions, therapy comes up most frequently as an issue for dis-
cussion.  The usual question is:  Which specific therapy is more efficacious?  In
practice, there are often answers provided by an understanding of mechanisms
of disease that differ from those suggested by the results of clinical trials.
The example of calcium channel blockers in the setting of myocardial is-
chemia discussed in the introduction is one of these controversies.  Other ex-
amples are common: first-line pharmacotherapy for depression (Serotonin Re-
uptake Inhibitors vs. Tricyclics), and treatment of patients with chronic lung
disease (Albuterol vs. Ipratropium).  Each of these examples shares the wide-
spread use of a medication because of the plausibility of its biological mecha-
nism in the absence of—or in spite of—empirical studies of its effect on out-
comes that matter to patients, such as survival, quality of life, functional status,
or satisfaction with care.
A. Clinical Policies
Decisions about therapy often have implications beyond individual patients,
because many emerging therapies have vast implications for the public and for
34. Eugene P. Goldberg, Evaluating the Health Risks of Breast Implants, 335 NEW ENG. J. MED.
1154, 1154 (1996).
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the organization of health care delivery systems.  An example is thrombolysis
for strokes.  For approximately fifteen years, a common treatment strategy for
acute myocardial infarction has been to give drugs that dissolve the clots inside
of the coronary vessels that precipitate myocardial infarction.  This strategy,
termed thrombolysis, has turned out to be useful in preserving myocardium, at
least temporarily.  Extending this thinking to the brain and to strokes, a number
of centers have been exploring the acute treatment of “brain attacks,” a com-
mon term for marketing this approach to the public.35
The argument in favor of thrombolysis rests on pathophysiological reason-
ing.  Many strokes are caused by clots in the blood vessels leading to the brain;
the clot stops blood supply to a part of the brain; without oxygen, that part of
the brain is irreversibly damaged.  Medications that alter the humours—in this
case, dissolve the clot—offer the possibility of preventing irreversible damage to
parts of the brain if given quickly.  From an empiricist view, the key issue is
whether such agents actually work:  Are strokes “prevented” or limited in size
such that functional status, quality of life, and survival are improved?
The stakes are large.  The medication is very expensive—$1200 to $1300 per
dose—and as this becomes the standard of care, it will mean extensive public
awareness campaigns and dramatic changes in our emergency medical transport
system.  A single large trial has added substantial impetus to this change in
clinical policy. 36  Six hundred twenty-four subjects with symptoms for less than
three hours were randomized to TPA, a clot dissolving agent, or to a placebo.
Patients receiving TPA had increased numbers of intracranial hemorrhages,
but, despite that, a trend to better survival and significantly better function at
three months by four different functional measures.37  The number of patients
that needed treating to have one patient do substantially better was 8-11, an
important and impressive result.38
Unfortunately, the picture is not so simple, despite the enthusiasm around
the trials.  Table 1 summarizes the other major randomized clinical trials of
thrombolysis for strokes, with numbers of patients, drug, duration of symptoms,
and outcomes.  The other clinical studies are different in important ways (drug
chosen, timing of medication) but are impressive for their poor outcomes.39
Moreover, clinical experience with thrombolysis has underscored a variety of
important preclinical issues in addition to efficacy.  Almost all patients do not
35. See National Inst. of Neurological Disorders, Stroke rt-PA Stroke Study Group, Tissue Plas-
minogen Activator for Acute Ischemic Stroke, 333 NEW ENG. J. MED. 1581 (1995).
36. See id.
37. See id.
38. See id.
39. See G.A. Donnan et al., Trials of Streptokinase in Severe Acute Ischaemic Stroke, 345 LANCET
578 (1995); European Cooperative Acute Stroke Study, Intravenous Thrombolysis with Recombinant
Tissue Plasminogen Activator for Acute Hemispheric Stroke, 274 JAMA 1017 (1995); Multicentre Acute
Stroke Trial–Italy (MAST-1) Group, Randomised Controlled Trial of Streptokinase, Aspirin, and Com-
bination of Both in Treatment of Acute Ischaemic Stroke, 346 LANCET 1509 (1995); Multicentre Acute
Stroke Trial–Europe Study Group, Thrombolytic Therapy with Streptokinase in Acute Ischaemic Stroke,
274 JAMA 1017 (1995).
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arrive within the critical three-hour window; in one trial, despite a substantial
community awareness program, less than one percent of patients with strokes
were captured.40  Moreover, for patients who do arrive in time, the exclusion of
hemorrhagic strokewhich is necessary before thrombolytics can be given
safelyis error prone, even when performed by experienced academic physi-
cians. 41
The case of thrombolysis illustrates how the tension between mechanisms of
disease and empiricism plays out in consideration of a new generation of treat-
ment in our society.  The animus for the intervention comes from understanding
the mechanism of disease; the idea gains support from investigators, academic
medical centers, and industry, supporting a major federal trial—a concession to
the value of empiricism.  With a single positive trial, and with extensive public-
ity, this treatment is becoming the standard of care, despite many concerns
about efficacy and overall effectiveness.42  As adverse events occur, there will be
ample documentation of the dangerousness and lack of practicality of the drugs.
TABLE 1:
THROMBOLYSIS FOR STROKES
Study N Drug Time Outcome
MASTI 622 Streptokinase 6 hours kills
MASTE 310 Streptokinase 6 hours kills
ASK 340 Streptokinase 4 hours kills/maims
ECASS 620 TPA 6 hours kills, but. . .
B. How to Choose Optimal Therapy for an Individual Patient
Often the appropriate choice of therapy for an individual patient is at issue.
Clinicians with a traditional perspective emphasize the importance of using
what is known about pathophysiology to make decisions about therapy.  So, for
a patient in an intensive care unit setting, discussion of the physiology of the pa-
tient is the necessary preface for deciding on treatment.  In contrast, enthusiasts
of Evidence-Based Medicine argue that the best estimate of an individual re-
sponse to therapy is the average response of a group to that therapy.
40. See P.B. Fontanarosa & M.A. Winker, Timely and Appropriate Treatment of Acute Stroke, 279
JAMA 1307 (1998).
41. See D.L. Schriger et al., Cranial Computed Tomography Interpretation in Acute Stroke, 279
JAMA 1293 (1998).
42. In clinical epidemiology, there is an important distinction between efficacywhether a treat-
ment will work under ideal conditions of a funded clinical trial, with highly selected clinicians and pa-
tients, financial incentives for both clinicians and patients, free treatment and medical and support staff
to monitor patients—and effectiveness—whether a treatment will work in usual conditions, with usual
clinicians and patients and no special reimbursement or monitoring.
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Both viewpoints have their limits.  Our understanding of pathophysiology in
individual cases is often limited and provides a shaky basis for therapy that im-
proves long-term patient outcomes.  So, too, is what evidence-based practice
can say.  As Alvan Feinstein has underscored,43 for many clinical problems, no
available high quality clinical information (such as randomized controlled trials)
is available.  Generalizing information from subgroup analyses of clinical trials
is fraught with potential error, and the amount of work necessary to have con-
tinually updated information poses a further practical barrier.
VII
MODERN MEDICINE: DIAGNOSIS
A. Pattern Recognition versus Bayesian Analysis
The remaining fundamental clinical questions—diagnosis and prognosis—
are not a primary focus of either the rationalist or the empiricist traditions.  Nev-
ertheless, the tension between the traditions persists in current clinical care and
its associated litigation.  The classic mode of diagnosis of a traditional rationalist
approach is of pattern recognition—the recognition of the signs and symptoms
that are external manifestations of an inner disease whose cause is known.
Thus, Hippocrates emphasized key features of particular diseases, such as ma-
laria with a fever every three days.44  An excellent modern statement of this is
by Nicholas A. Vick in one of the major textbooks of neurology.45  Vick explains
that
a complete and thorough neurological examination may be fitted together like a jig-
saw puzzle . . . . [T]he symptoms described by the patient . . . suggest disease of certain
structure, whose function then should be tested thoroughly with more exact meth-
ods . . . . [A]n understanding of clinical neurology cannot be reached merely by memo-
rizing signs and symptoms of diseases.46
By contrast, diagnostic reasoning in many clinical settings is probabilistic or
Bayesian47 and reflects the impact of context or prevalence of disease in a par-
ticular setting.  An excellent example is the performance of diagnostic tests in
different populations.  One of the best diagnostic tests available in clinical
medicine is the diagnostic test for HIV, which has sensitivity and specificity well
above ninety-five percent.  Yet the performance of that diagnostic test is dra-
matically dependent on the prevalence of the disease in the population being
tested.  Thus, a positive test in the Castro district of San Francisco (which has a
43. See Alvan R. Feinstein & Ralph I. Horwitz, Problems in Evidence of Evidence-Based Medicine,
103 AM. J. MED. 529, 531-32 (1997).
44. See generally MAJOR, supra note 4, at 115-38.
45. See NICHOLAS A. VICK, GRINKER’S NEUROLOGY (7th ed. 1976).
46. Id. at 4.
47. In Bayesian statistics (sometimes called subjectivist statistics), an investigator assigns a subjec-
tive “prior” probability to a hypothesis.  The application of Bayes’ rule (or theorem) to collected data
permits the computation of a “posterior” probability that expresses the investigator’s belief about the
validity of the hypothesis.  See Kaye & Freedman, supra note 31, at 152-53, 160.
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high prevalence of HIV) is almost always a true positive.  The positive predic-
tive value is almost 100%.  If one gets a positive test, one can be comfortable
describing the test as “almost definite.”  However, in a positive for a patient in a
rural area of North Carolina with a much lower prevalence of HIV, the likeli-
hood of a false positive test is much higher—as high as fifty percent or sixty per-
cent, depending on the population.  The test is the same, but it performs differ-
ently in different populations.
The contrast is between the two modes of diagnosis.  One—pattern recogni-
tion—hearkens back to a rationalist ancestry that emphasized a single cause for
a disease; it is a single-step process and is independent of location.  The other,
which comes out of empiricist lineage with its modern mathematical framework,
is dependent on context.  The difference between these perspectives at the
clinical point of service animates many disagreements among clinicians, expert
witnesses, and policymakers.48
B. Early Diagnosis of Disease: Screening for Breast Cancer in Women
between Forty and Fifty
Controversies over routine screening provide an example of how different
approaches to evidence combined with politics lead to dramatic differences in
recommendations by different expert bodies.  For more than a generation, the
American Cancer Society (“ACS”) has promoted early screening for all types
of cancer.49  Relying on informal expert panel advice, they have developed and
maintained a set of recommendations for screening.50  The general approach is
screen early, screen often, screen as much as possible.  The unifying theory is
based on an understanding of the pathology of cancer:  Cancers spread; earlier
cancer has spread, and cure is more likely if the cancer is treated before it
spreads widely.  For breast cancer, this has translated to a recommendation for
screening for all women starting at thirty-five.51
In contrast, from the empiricist perspective, a number of organizations have
attempted over the last twenty-five years to make recommendations for preven-
tion based on what clinical trials show about the outcomes of screening.  Build-
ing on the work of the Canadian Task Force on the Periodic Exam and the
work of Paul Frame, the United States Preventive Services Task Force
(“USPSTF”) has set explicit criteria for reviewing clinical preventive services.52
These criteria include the burden of suffering, the characteristics of the test
(sensitivity, specificity, and side effects) and particularly the evidence about ef-
48. Disagreements about the use and value of specific diagnostic tests or maneuvers are common.
An excellent introduction to this issue, along with many clinical examples, is found in SACKETT, supra
note 17, at 3-155.
49. For the American Cancer Society’s recommendations for screening, see <http.www.cancer.
org> (visited May 2, 2001).
50. See id.
51. See id.
52. See U.S. PREVENTIVE SERVICES TASK FORCE, GUIDE TO CLINICAL PREVENTIVE SERVICES
(2d ed. 1996).
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fectiveness, that is, the impact on morbidity or mortality as shown in clinical
studies.  For screening for breast cancer in women between forty and fifty, the
results of clinical trials have been mixed, with at least one major properly per-
formed trial showing no benefit of screening.53  As a consequence, the last edi-
tion of the USPTF gave screening for breast cancer between forty and fifty
years a “C” grade, meaning no good evidence supports routine screening.54
While this specific recommendation may change as the result of recent data re-
porting longer follow-up periods, the population impact of screening for forty-
to fifty-year-olds is so small that support for routine screening will be tepid,
emphasizing informed consent of the patient’s role in the process.
In summary, both the process and the specific recommendations of the ACS
and the USPSTF are very different, and the controversy about recommenda-
tions for breast cancer screening for women between forty and fifty has been
noisy.55  The controversy reflects different underlying approaches to evi-
dencerationalist and empiricistamplified by the emotional and political sa-
lience of the disease.
VIII
MODERN MEDICINE: PROGNOSIS
The tension between rationalism and empiricism also informs how modern
medicine addresses prognosis.  Along with causation, therapy, and diagnosis,
prognosis is one of the fundamental questions of clinical medicine; without
knowledge of prognosis, or the natural history of disease, it is difficult to know
whether and how to treat.  The rationalist worldview, however, has as its pri-
mary focus the causation of disease.  What happens next, in terms of the pro-
gression of symptoms and morbidity or mortality, is of secondary importance.
By contrast, the empiricist tradition has always been much more attentive to the
particularities of the natural history of disease.
The dominance of the rationalist worldview, together with an American in-
sistence on cure as quickly as possible, is reflected in the published medical lit-
erature and its lack of attention to prognosis.  Working with colleagues, I re-
viewed all the articles with pneumonia as a Medical Subject Heading term in an
entire year.  We chose pneumonia because it is very common and remains one
of the top contributors to mortality for people over sixty-five years old.  We re-
53. See A.B. Miller et al., Canadian National Breast Screening Study:  Breast Cancer Detection and
Death Rates Among Women Aged 40-49 Years, 147 CAN. MED. ASSOC. J. 1459, 1459-76 (1992).
54. See id.
55. The controversy involved the leadership of the National Cancer Institute.  A good introduction
to the science of the controversy is a set of articles in Annals of Internal Medicine.  See Russell Harris &
Linda Leininger, Clinical Strategies for Breast Cancer Screening: Weighing and Using the Evidence, 122
ANNALS INTERNAL MED. 539 (1995); Edward A. Sickles & Daniel B. Kopanos, Mammographic
Screening for Women Aged 40-49 Years of Age:  The Primary Care Practitioner’s Dilemma, 122
ANNALS INTERNAL MED. 534 (1995).
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viewed a total of 1147 articles; as Figure 2 depicts, articles on prognosis were
rare and significantly less common than articles on treatment.56
The inattention to prognosis is more fundamental than the lack of research
attention; it also relates to the inexact linkage between diagnosis and prognosis.
As Alvan Feinstein has argued, ideally diagnostic terminology should include
some component of prognosis.  For example, there should be a strong linkage
between the stage of a cancer and the prognosis.  A stage I cancer should live
longer than stage II, and so on.  Often, however, our staging mechanisms are
based in our understanding of pathology—the spread of the cancer through
specific tissues—rather than prognosis.57  For cancers, this has often taken the
form of staging systems that describe the size of the tumors, involvement of
lymph nodes, and the presence of metastases.  This is the so-called TNM sys-
tem, and, for many cancers, several TNM classes are grouped into stages (A-D
or I-IV).
For Feinstein, the prognostic implications of diagnosis are critical, and he
has described an alternate classification system based on symptoms and co-
morbidity as well as pathology, with an emphasis on features that were easily
apparent to the physician, such as the presence of such specific symptoms as
pain or anorexia, and co-morbidity such as heart failure.58  Feinstein has de-
scribed this alternate kind of system with a wide variety of diseases.59  Table 2
compares the performance of his system against the traditional approach to
staging for cancer of the larynx.  The Feinstein system predicts survival much
better; the table underscores the prognostic variation within traditional disease
classification.
From the perspective of the argument of this paper, prognosis is not funda-
mentally important to the rationalist vision, and the classification systems based
on mechanisms of disease address it only imperfectly.  This case (and many oth-
ers) shows the dramatic improvement in power by inclusion of the relatively
simple information within the grasp of the practitioner.  It is a measure of the
strength of the rationalist worldview in current clinical medicine that classifica-
tion systems have not changed markedly.
The renaissance of empiricism has led to a return of an emphasis on progno-
sis in the organization of clinical care.  An excellent example is the development
of clinical care pathways based on prognosis.  These have spread through hospi-
tals over the last ten years as a way of standardizing and improving the quality
of care.  The management of chest pain provides an example.  Traditionally, the
hospital evaluation of chest pain was focused on diagnosis—whether there had
been a myocardial infarction.  This assessment was based on a combination of
cardiac enzymes, the electrocardiogram, and the clinical setting—the recogni-
56. See Figure 2 in the Appendix.
57. See Alvan Feinstein, Cancer of the Larynx:  A New Staging System and a Re-Appraisal of Prog-
nosis and Treatment, 30 J. CHRONIC DISEASES 277 (1977).
58. See id.
59. See id.
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tion of the disbalance of the humours.  Over the last five years, a major new ap-
proach to diagnosing myocardial infarctions has been described and evalu-
ated—the use of Troponins.  This new test was justified by its link to prognosis.60
Moreover, most new clinical pathways for chest pain have prognosis as their
central organizing principle, focusing on separating out low-risk individuals
from high-risk, not directly related to the presence or absence of myocardial in-
farction.  This approach is being applied in a large range of clinical settings,
from febrile infants to the frail elderly.
TABLE 2
COMPARISON OF STAGING SYSTEMS FOR CANCER OF LARYNX
(% 5-YEAR SURVIVAL)
Clustered TNM stagesComposite
S-A-C
Stages I II III IV Total
Alpha 85% 100% 100% — 88%
Beta 64% 100% 42% — 60%
Gamma 63% 50% 36% — 44%
Delta 22% 100% 17% 8% 15%
Total 67% 82% 36% 8% 50%
Source:  Alvan Feinstein, Cancer of the Larynx:  A New Staging System and a Re-Appraisal
of Prognosis and Treatment, 30 J. CHRONIC DISEASES 277, 277-305 (1977).
IX
CONCLUSION
There is an important difference in ways of thinking between empiricists
and rationalists.  This tension was present in its most stark form in ancient times
with the often-bitter clash of rationalists and empiricists.  At its founding, mod-
ern medicine represented a triumphal return of the rationalists.  Their insis-
tence on understanding the mechanisms of disease has been architectonic for
modern clinical medicine.  For all its rhetoric of novelty, Evidence Based Medi-
cine represents a counter-revolution of traditional empiricism, draped in mod-
ern clothes of statistics and multi-variate analysis.  The tension between ration-
alism and empiricism abides and finds its expression in a wide variety of clinical
questions.  The culture war within medicine starts with causation and extends to
60. For an example of a pathway based on prognosis, see Christian Hamm et al., Emergency Room
Triage of Patients with Acute Chest Pain by Means of Rapid Testing for Cardiac Troponin T or Tro-
ponin I, 337 NEW ENG. J. MED. 1648 (1997).  See also AGENCY FOR HEALTH CARE POLICY AND
RESEARCH, NATIONAL HEART, LUNG, AND BLOOD INSTITUTE, UNSTABLE ANGINA: DIAGNOSIS
AND MANAGEMENT CLINICAL PRACTICE GUIDELINE NO. 10 (1994).
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the other fundamental clinical questions—diagnosis, prognosis, and treatment—
which are at the center of clinical disagreements, private injuries, and policy de-
bates.
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APPENDIX
FIGURE 1:
INDICATIONS FOR DILTIAZEM (AUGUST 1991)
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FIGURE 2:
PROGNOSIS IN THE LITERATURE
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